Results 21 to 30 of about 36,261 (106)

Relapsing polychondritis

open access: yesDermatology Online Journal, 2003
A 57-year-old man presented with a 2-year history of (1) recurrent swelling of the ears that spared his earlobes and (2) migratory arthralgias. A biopsy specimen of the ear showed a perichondrial infiltrate of lymphocytes, plasma cells, and a few neutrophils. There were acellular foci of underlying cartilage.
Alatas, FÜSUN   +5 more
  +10 more sources

Bilateral Anterior Uveitis Revealing Relapsing Polychondritis [PDF]

open access: yes, 2019
Relapsing polychondritis is a potentially lethal but rare systemic autoimmune disease. The major site of inflammation is the connective tissue, usually involving the ears, nose, larynx, tracheobronchial tree, and cardiovascular system. Although scleritis
Aktaş, Zeynep   +14 more
core   +1 more source

Relapsing polychondritis [PDF]

open access: yesClinical Radiology, 1988
Relapsing polychondritis is a progressive multisystem disorder that predominantly affects cartilage, producing an inflammatory reaction. We present case histories from four patients having mainly respiratory symptoms in whom we measured the coronal diameters of the trachea and compared them with the tracheal measurements from radiographs of patients ...
M P, Crockford, I H, Kerr
openaire   +4 more sources

LIMBIC ENCEPHALITIS ASSOCIATED WITH RELAPSING POLYCHONDRITIS RESPONDED TO INFLIXIMAB AND MAINTAINED ITS CONDITION WITHOUT RECURRENCE AFTER DISCONTINUATION : A CASE REPORT AND REVIEW OF THE LITERATURE [PDF]

open access: yes, 2014
2014-08Central nervous system (CNS) manifestations are rare complications of relapsing polychondritis (RP). The majority of patients respond well to glucocorticoid therapy, but need to maintain it.
SATO, JUICHI   +11 more
core   +1 more source

Relapsing Polychondritis Following Alopecia Areata [PDF]

open access: yes, 2010
A case of alopecia areata followed by relapsing polychondritis is presented. Similar cases from the literature are reviewed and speculation about the relationship of these diseases is offered. Although the occurrence of these diseases together could be
George W. Brasher   +2 more
core   +1 more source

Relapsing Polychondritis

open access: yesJMA Journal, 2019
Abstract Relapsing polychondritis (RPC) is a unique and rarely observed autoimmune condition regarded as recurrent extensive chondritis of the auricular, nasal, and tracheal cartilages. Moreover, heart, main arteries, skin, and eyes may be involved. Several forms of clinical manifestations may be seen, and the pathogenesis still remains anonymous.
Taniyama, Daisuke   +2 more
openaire   +6 more sources

Relapsing Polychondritis [PDF]

open access: yesEar, Nose & Throat Journal, 2002
Relapsing polychondritis (RP) is a rare disease causing inflammation and destruction of cartilage and other connective tissues. Specific laboratory aberrations are lacking. Predominant clinical manifestations include auricular chondritis, polyarthritis, nasal chondritis, ocular inflammation, audiovestibular damage, and respiratory tract chondritis.
Bruce A, Staats   +2 more
openaire   +4 more sources

The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis

open access: yes, 2018
Objectives: Relapsing polychondritis is a rare, multi-systemic and inflammatory condition of unknown origin. We currently lack a core set of measures to assess and follow damage in patients suffering from this condition.
Damian, Laura   +27 more
core   +4 more sources

Management of Auricular Hematoma With Bolster Versus Quilting: A Retrospective Cohort Study

open access: yesThe Laryngoscope, EarlyView.
This retrospective cohort study compared outcomes between bolster dressings and through‐and‐through mattress quilting sutures in the management of auricular hematoma in 43 patients. Recurrent hematoma occurred in 30% of the bolster group and 0% of the quilting group, with no significant differences in complications observed between the two groups ...
Christie F. Cheng   +3 more
wiley   +1 more source

Indicators of Suboptimal Treatment Among Patients With Crohn's Disease Treated With Ustekinumab or Risankizumab and Treatment Journey Among Ustekinumab Discontinuers in the United States

open access: yesJCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Patients with Crohn's disease (CD) may experience suboptimal response to advanced therapies (ATs), including interleukin (IL)‐12/23 inhibitor ustekinumab and IL‐23 inhibitor risankizumab. In an evolving treatment landscape, this study evaluated indicators of suboptimal treatment with these agents. Methods This retrospective
Freddy Caldera   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy